Paper Details

  1. Home
  2. Paper Details

Long-term follow-up of a phase III study of recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid malignancies.

Author: BiermanP J, DemetriG, FreedmanA S, MauchP, NemunaitisJ, NeubergD, OnettoN, RabinoweS N, SingerJ W, VoseJ M

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Overview

rhGM-CSF showed no apparent long-term adverse effects on bone marrow function after autologous bone marrow transplantation (ABMT) for non-Hodgkin's lymphoma, Hodgkin's disease, and acute lymphoblastic leukemia.
Paper Details　
Original Abstract of the Article :
One hundred and twenty-eight patients with non-Hodgkin's lymphoma (NHL), Hodgkin's disease (HD), and acute lymphoblastic leukemia (ALL) previously reported from a phase III trial of rhGM-CSF or placebo following autologous bone marrow transplantation (ABMT) were investigated for the development of l...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/8461475

データ提供：米国国立医学図書館（NLM）

Long-Term Follow-Up of a Phase III Study of rhGM-CSF After Autologous Bone Marrow Transplantation

Bone marrow transplantation is a life-saving procedure for patients with certain cancers. This study examines the long-term safety and efficacy of recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) after autologous bone marrow transplantation (ABMT) for lymphoid malignancies. The researchers aimed to assess the long-term effects of rhGM-CSF on patient outcomes and identify factors that may predict recovery from transplantation.

Navigating the Desert of Bone Marrow Transplantation

The study found no evidence of long-term adverse effects of rhGM-CSF on bone marrow function or patient survival. However, the researchers identified factors such as the diagnosis of acute lymphoblastic leukemia (ALL) and prior exposure to stem cell-depleting agents that can affect recovery after ABMT.

Finding Oasis in the Desert of Transplantation

This study provides valuable insights into the long-term safety and efficacy of rhGM-CSF after ABMT, highlighting the importance of careful patient selection and management. The findings contribute to the ongoing understanding of bone marrow transplantation and guide clinical practice in this complex area of medicine.

Dr. Camel's Conclusion

This study is like a camel caravan meticulously navigating the desert of bone marrow transplantation, providing a roadmap for ensuring the best possible outcomes for patients undergoing this life-saving procedure. The findings shed light on the importance of considering individual factors and optimizing care to ensure successful recovery and a brighter future for these individuals.

Date :
  1. Date Completed 1993-05-04
  2. Date Revised 2021-02-16
Further Info :

Pubmed ID

8461475

DOI: Digital Object Identifier

S0006-4971(20)79203-7

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.